StreetInsider.com News Articles

Artelo drug shows pain reduction in nonclinical neuropathy model

Mon, 13 Jul 2026 09:02:37 -0400

Artelo Biosciences (NASDAQ: ARTL) reported that its drug candidate ART27.13 reduced neuropathic pain-associated behaviors in a nonclinical model of paclitaxel-induced peripheral neuropathy, according to a press release from the clinical-stage pharmaceutical company.

Researchers found that repeated dosing with ART27.13 reduced mechanical allodynia and thermal hyperalgesia in both male and female animals treated with paclitaxel, a chemotherapy agent. Paclitaxel-induced peripheral neuropathy affects an estimated 60% to 80% of patients receiving the drug.

The findings were presented by George Warren, Ph.D., lead scientist at Artelo Biosciences, at the International Cannabinoid Research Society 2026 Annual Symposium held in Dijon, France.

"The results observed in this model

Artelo drug shows pain reduction in nonclinical neuropathy model

Mon, 13 Jul 2026 09:02:37 -0400

The findings were presented by George Warren, Ph.D., lead scientist at Artelo Biosciences, at the International Cannabinoid Research Society 2026 Annual Symposium held in Dijon, France.

"The results observed in this model

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Mon, 13 Jul 2026 09:02:00 -0400

Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer

Findings suggest broader utility in cancer supportive care, building on interim findings from CAReS Phase 2 clinical study which demonstrated improvements in body weight, lean body mass and activity levels

SOLANA BEACH, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced promising

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Mon, 13 Jul 2026 09:02:00 -0400

Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Mon, 13 Jul 2026 09:02:00 -0400

Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Mon, 13 Jul 2026 09:02:00 -0400

Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer

Form DEFA14A ARTELO BIOSCIENCES, INC.

Thu, 02 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26727532.html

Form DEFA14A ARTELO BIOSCIENCES, INC.

Thu, 02 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26727532.html

Artelo reports preclinical data on ART26.12 for spinal cord injury pain

Wed, 01 Jul 2026 08:44:09 -0400

Artelo Biosciences, Inc. (NASDAQ: ARTL) announced preclinical data showing that its drug candidate ART26.12 reduced neuropathic pain associated with spinal cord injury in a mouse model, according to a company press release.

The findings were presented at the International Cannabinoid Research Society 2026 Annual Symposium in Dijon, France, by Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University. The presentation was titled "Inhibition of Fatty Acid Binding Protein 5 Alleviates Neuropathic Pain Following Spinal Cord Injury in Mice."

In the study, selective inhibition of fatty acid binding protein 5 (FABP5) by ART26.12 produced four observed effects in the animal model: reduced

Artelo reports preclinical data on ART26.12 for spinal cord injury pain

Wed, 01 Jul 2026 08:44:09 -0400

In the study, selective inhibition of fatty acid binding protein 5 (FABP5) by ART26.12 produced four observed effects in the animal model: reduced

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury